trending Market Intelligence /marketintelligence/en/news-insights/trending/10z6mwm3rkwhvoupficr8g2 content esgSubNav
In This List

IntelGenx drops plans to buy pharmaceutical consulting firm

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet

Blog

Insight Weekly: Stocks limp into 2023; GCC banks set for rebound; deep-sea mining faces pushback

Infographic

Infographic: The Big Picture 2023 Sustainability Outlook

Blog

The Big Picture for 2023: Assessing Investment Trends and the Impact of Investor Activism


IntelGenx drops plans to buy pharmaceutical consulting firm

IntelGenx Technologies Corp. said March 27 that it is no longer looking to raise $10 million to fund the acquisition of a pharmaceutical consulting firm.

The company canceled its placement due to market conditions. The Canadian drug delivery company's acquisition of LaboVal Inc. was dependent on the financing.